Found: 5
Select item for more details and to access through your institution.
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-28647-4
- By:
- Publication type:
- Article
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
- Published in:
- Journal of the American Heart Association, 2023, v. 12, n. 23, p. 1, doi. 10.1161/JAHA.123.031241
- By:
- Publication type:
- Article
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 21, p. 3482, doi. 10.3390/cells11213482
- By:
- Publication type:
- Article
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1140730
- By:
- Publication type:
- Article
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
- Published in:
- Cellular Oncology (2211-3428), 2024, v. 47, n. 2, p. 695, doi. 10.1007/s13402-023-00893-8
- By:
- Publication type:
- Article